Cardiff Oncology Inc expected to post a loss of 25 cents a share - Earnings Preview

Reuters05-01

* Cardiff Oncology Inc is expected to show a fall in quarterly revenue when it reports results on May 2 for the period ending March 31 2024

* The San Diego California-based company is expected to report a 33.7% decrease in revenue to $55 thousand from $83 thousand a year ago, according to the mean estimate from 4 analysts, based on LSEG data.

* ​LSEG's mean analyst estimate for Cardiff Oncology Inc is for a loss of 25 cents per share.

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The mean earnings estimate of analysts was unchanged in the last three months. ​

* Wall Street's median 12-month price target for Cardiff Oncology Inc is $10.50​, above​ its last closing price of $4.36. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI

ENDING ARTESTIMAT ESTIMATE MET, SE %

E® MISSED

Jan. 1 0001 -0.27 -0.28 -0.21 Beat 24.3

Sep. 30 0001 -0.28 -0.28 -0.22 Beat 22.8

Jun. 30 2023 -0.28 -0.26 -0.25 Beat 3.5​

Mar. 31 2023 -0.22 -0.23 -0.25 Missed -10.6

​​Dec. -0.22 -0.23 -0.20 Beat 14.9

31 2022

Sep. 30 2022 -0.27 -0.26 -0.20 Beat 24.2​

Jun. 30 2022 -0.26 -0.25 -0.24 Beat 4.8

Mar. 31 2022 -0.25 -0.23 -0.25 Missed -8.2

This summary was machine generated April 30 at 22:46 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment